Over FY20-22, the company's consolidated sales increased at a CAGR of 23 per cent, headed by the headed lighting segment, which increased at a CAGR of 24 per cent during the same period.    

Operating profit stood at Rs 146 crore, an impressive jump of 102.77per cent over FY22.

Meropenem, a vital antibiotic for life-threatening infections, contributes 40 per cent to total sales. Venus Remedies launched it successfully in major European markets, securing 120+ marketing authorizations in countries like UK, France, Germany, UAE, and Australia. European market size: USD 70.34 million.

The company has delivered returns of 51 per cent over the past 3 years and returns of 74 per cent over the past 5 years. Moreover, the company has a healthy dividend payout ratio of 61.4 per cent.

On Friday, at 03:30 pm, indices ended the trading session in red with the BSE Sensex Index down 0.41 per cent at 62,979.37 and the NSE Nifty-50 Index down 0.56 per cent at 18,665.50. 

The benchmark indices are expected to open slightly higher today, influenced by the positive start indicated by the SGX Nifty. The SGX Nifty began the session at 18,859 points and showed a gain of 51 points. In early trade on June 23, SGX futures reached a high of 18,923 points.

As of the quarter ended March 2023, the promoters of MTAR Technologies held approximately 46.63 per cent stake in the company. What has piqued interest is the fact that since the quarter ended June 2022, the percentage of pledged shares in relation to promoter holding has been on the rise.

The company's stock has been on a remarkable upward trajectory, delivering multibagger returns of over 700 per cent in the past three years. This impressive performance can be attributed to several factors, including the efficient management of the company and its commitment to growth and profitability.  

The stock has jumped more than 300 per cent in the last 6 months.

Shares of the company saw a spurt in volume by more than 3.56 times on BSE.